Brian Harvey - Adicet Bio Chief Officer
| ACET Stock | USD 0.90 0.01 1.12% |
Insider
Brian Harvey is Chief Officer of Adicet Bio
| Age | 64 |
| Address | 131 Dartmouth Street, Boston, MA, United States, 02116 |
| Phone | 650 503 9095 |
| Web | https://www.adicetbio.com |
Brian Harvey Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Harvey against Adicet Bio stock is an integral part of due diligence when investing in Adicet Bio. Brian Harvey insider activity provides valuable insight into whether Adicet Bio is net buyers or sellers over its current business cycle. Note, Adicet Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Adicet Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Harvey over a month ago Disposition of 8752 shares by Brian Harvey of Adicet Bio at 0.9218 subject to Rule 16b-3 |
Adicet Bio Management Efficiency
The company has return on total asset (ROA) of (0.335) % which means that it has lost $0.335 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5804) %, meaning that it created substantial loss on money invested by shareholders. Adicet Bio's management efficiency ratios could be used to measure how well Adicet Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.75 in 2025. Return On Capital Employed is likely to gain to -0.88 in 2025. Total Current Liabilities is likely to drop to about 16.5 M in 2025. Liabilities And Stockholders Equity is likely to drop to about 165.2 M in 2025Similar Executives
| Showing other executives | INSIDER Age | ||
| Marcy Graham | Aadi Bioscience | 57 | |
| James Trager | Nkarta Inc | 61 | |
| T Washburn | Agios Pharm | 43 | |
| Rik Derynck | Pliant Therapeutics | N/A | |
| Peter MD | Acrivon Therapeutics, Common | 62 | |
| Deepak MD | Tenaya Therapeutics | 59 | |
| Corinne Savill | Cullinan Oncology LLC | 66 | |
| Suzette Tauber | IGM Biosciences | 61 | |
| CBE FMedsci | Bicycle Therapeutics | 71 | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| Shinyu MD | IGM Biosciences | 55 | |
| MBA MBA | Bicycle Therapeutics | 43 | |
| Hunter MD | Aerovate Therapeutics | 59 | |
| KeeHong Kim | Tenaya Therapeutics | 59 | |
| Yvonne MBA | Nkarta Inc | 64 | |
| Bryan Ball | Aadi Bioscience | 54 | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| MBA MD | Vor Biopharma | 47 | |
| Jasbir Seehra | Keros Therapeutics | 69 | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.33 |
Adicet Bio Leadership Team
Elected by the shareholders, the Adicet Bio's board of directors comprises two types of representatives: Adicet Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adicet. The board's role is to monitor Adicet Bio's management team and ensure that shareholders' interests are well served. Adicet Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adicet Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Francesco MD, Chief VP | ||
| BA CPA, Pres CEO | ||
| Blake Aftab, Senior Officer | ||
| Donald Healey, Chief Officer | ||
| Amy Locke, Head Resources | ||
| Brian Harvey, Chief Officer | ||
| Julie MD, Chief Officer | ||
| Aya Jakobovits, Founder Director |
Adicet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adicet Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | (109.52 M) | ||||
| Shares Outstanding | 82.4 M | ||||
| Shares Owned By Insiders | 2.75 % | ||||
| Shares Owned By Institutions | 69.45 % | ||||
| Number Of Shares Shorted | 2.97 M | ||||
| Price To Earning | 36.84 X | ||||
| Price To Book | 0.35 X | ||||
| Price To Sales | 9.72 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.